The company diverges from Summit and Bristol/BioNTech with a pivotal endometrial trial.
ApexOnco Front Page
Recent articles
Parabilis’s zolucatetide bids to be third to a rather small market.
The biggest oncology buy of the quarter concerned the prostate cancer player Halda.
And the company says it won’t need to carry out another trial.
Takeda picked up IBI363 for $1.2bn, and now Innovent advances IBI3026.
The “next-gen” PF-07985045 is gone, but the group has another pan-KRAS shot.
And that could affect the drug's third-line accelerated approval.
A fresh licensing deal tidies up years of work between the two companies.
